The 3D PATH project was successfully presented at the 4th edition of the Artificial Intelligence (AI) for Oncology and Cancer Research Conference, held in Milan, Italy on May 7–8, 2026. by project partner Clepio Biotech.
At the event, the team presented a scientific poster titled “A novel 3D tissue twin technology enabling new AI for precision medicine.” The presentation highlighted the innovative approach of 3D PATH in transforming digital pathology through the integration of volumetric imaging and artificial intelligence.
The project aims to overcome the limitations of conventional 2D histopathology by generating high-resolution 3D digital tissue twins of intact biological samples. By combining light-sheet microscopy, advanced tissue processing, and AI-ready data architectures, 3D PATH seeks to create more realistic and reliable datasets for precision oncology.
Within the 3D PATH consortium, ACMIT plays a key role in developing a certification-ready version of the light-sheet microscope. In addition, ACMIT is responsible for regulatory affairs management, supporting alignment with medical device standards and facilitating the pathway toward clinical adoption.
The event enabled the 3D PATH team to build collaborations, exchange expertise, and explore the role of 3D pathology and AI in personalized cancer treatment.
For more information, please visit:
